Comparative Pharmacology
Head-to-head clinical analysis: MONOKET versus NITRO BID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MONOKET versus NITRO BID.
MONOKET vs NITRO-BID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Isosorbide mononitrate is a vasodilator that relaxes vascular smooth muscle via the release of nitric oxide (NO), which activates guanylate cyclase, increasing intracellular cGMP. This leads to venous and arterial dilation, reducing preload and afterload, thereby decreasing myocardial oxygen demand.
Nitroglycerin is a nitrate that relaxes vascular smooth muscle by conversion to nitric oxide (NO), which activates guanylate cyclase, increasing cyclic guanosine monophosphate (cGMP) levels, leading to vasodilation. Primarily dilates veins, reducing preload and myocardial oxygen demand; also dilates coronary arteries.
20 mg orally twice daily, 7 hours apart (e.g., 8 AM and 3 PM) to provide a nitrate-free interval.
Sublingual: 0.3-0.6 mg at onset of angina, may repeat every 5 minutes up to 3 doses. Transdermal: 0.2-0.8 mg/hour patch applied daily for 12-14 hours, then removed for 10-12 hours.
None Documented
None Documented
Terminal elimination half-life is approximately 5 hours (range 4–6 hours) for isosorbide mononitrate, consistent with a sustained duration suitable for once-daily dosing.
Terminal half-life of nitroglycerin is 1-4 minutes; clinical effects are short-lived due to rapid redistribution and metabolism.
Renal: approximately 98% of the dose is excreted in urine as metabolites (isosorbide mononitrate and its glucuronide conjugates); fecal excretion is minimal (<2%).
Renal: <1% unchanged; extensive metabolism followed by renal excretion of metabolites, with minor biliary/fecal elimination (<5%).
Category C
Category C
Nitrate Vasodilator
Nitrate Vasodilator